Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

NCT06586242 ·Status: RECRUITING ·Phase: PHASE2

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

NCT04063683 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

NCT05996484 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

NCT02649361 ·Status: COMPLETED ·Phase: PHASE2

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

NCT05990231 ·Status: UNKNOWN ·Phase: PHASE2

Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer

NCT01998347 ·Status: WITHDRAWN ·Phase: PHASE3

Apatinib as First -Line Treatment for Advanced Esophagus Cancer

NCT03542422 ·Status: UNKNOWN ·Phase: PHASE2

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

NCT01704690 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

NCT02034968 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06354530 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT04390958 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT06426797 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

NCT04804696 ·Status: TERMINATED ·Phase: PHASE2

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT04229849 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

NCT04437212 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

NCT03387904 ·Status: UNKNOWN ·Phase: PHASE2

High-dose Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer

NCT03535207 ·Status: UNKNOWN ·Phase: NA

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

NCT02976896 ·Status: COMPLETED ·Phase: PHASE2

Study of Apatinib in Metastatic Esophageal Cancer

NCT02683655 ·Status: UNKNOWN ·Phase: PHASE2

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

NCT06084897 ·Status: RECRUITING ·Phase: PHASE2

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

NCT05191667 ·Status: SUSPENDED ·Phase: PHASE1

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

NCT05252078 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT05740995 ·Status: RECRUITING

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

NCT05777707 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Radiation Dose Escalation in Esophageal Cancer

NCT03082586 ·Status: COMPLETED ·Phase: NA